当商品の販売は、2011年07月19日を持ちまして終了しました。
Abstract
Molecular Imaging Comes of Age: Applications and Impacts in Discovery,
Clinical Trials, and Medical Practice provides insight into the technologies
that will impact healthcare over the next five years from early research to the
delivery of care. The report presents a comprehensive assessment of the latest
trends and developments in molecular imaging, enhanced by the insights of
opinion leaders from industry and academia. A market outlook completes the
analysis.
Molecular imaging has become a business that covers the spectrum from basic
cell biology to drug discovery and disease monitoring. The forms in which it has
been commercialized are also highly diverse, indicating both substantial growth
opportunities for companies competing in this space, as well as new and improved
methodologies for researchers. Molecular Imaging Comes of Age evaluates the
competing technologies and their applications in three key areas:
Discovery
The pharmaceutical industry has placed a large bet on molecular imaging.
While monitoring and guiding of drug therapies with PET will help clinicians to
use drugs in a more targeted fashion, molecular imagings core role for the
pharmaceutical industry is in drug discovery and development. The report
examines ways in which pure research is already profiting from cell-based
molecular imaging, which will continue to be based on fluorescence,
bioluminescence, and confocal microscopy. Applications in small animal imaging,
lead characterization, and lead optimization are also discussed. The insights
into basic cell biology that this research is yielding today will form the basis
of drug development during the second half of the decade, as the results are
absorbed by the pharmaceutical industry.
Clinical Applications
The report highlights clinical applications of molecular imaging technology
in cancer, particularly ovarian cancer, as well as cardiovascular disease and
inflammation. Experimental clinical applications that reach far beyond these
fields, including for instance neuropsychiatry, angiogenesis, and the monitoring
of gene therapy are also covered.
Clinical Trials
All regulatory authorities demand that drug developers present a reasonable
amount of scientific proof for claims that the candidate compound binds to the
designated molecular target, or exerts the expected physiological effect in the
target tissue(s). In many cases, molecular imaging will be the method of choice
for obtaining such data. The report discusses the general regulatory issues that
will impact the use of imaging agents in clinical trials.
Table of Contents
- Chapter 1. The Basics of Imaging Technology
- 1.1. Tomography: "Virtual Slicing" and Reconstruction of
Three-Dimensional Objects
- 1.2. Tomography-Based Imaging Technologies
- -Structural Imaging Modalities
- --Computed Tomography (CT)
- --Magnetic Resonance Imaging (MRI)
- 1.3. Emission-Based Tomography Methods
- -Positron Emission Tomography (PET)
- -Single-Photon Emission Computed Tomography (SPECT)
- 1.4. Combined Structural and Functional Imaging Modalities
- 1.5. Optical Technologies
- -Diffuse Optical Tomography (DOT)
- -Optical Coherence Tomography (OCT)
- -Confocal Laser Scanning Microscopy (CLSM) and its Derivatives
- --Fluorescence Correlation Microscopy (FCM)
- --Fluorescence Resonance Energy Transfer (FRET)
- --Fluorescence Lifetime Imaging (FLIM)
- --Fluorescence Recovery after Photobleaching (FRAP) and
Fluorescence Loss in -Photobleaching (FLIP)
- -"Standard" Fluorescence and Bioluminescence
- -Optical Spectroscopy Imaging
- 1.6. A Limited Role for Ultrasound
- Chapter 2. Molecular Imaging Targets and Probes
- 2.1. Classes of Targets for Molecular Imaging
- -Receptors, Ion Channels, and their Functional State
- -Enzymes
- -Antigens and Specific Binding Proteins
- -Nucleic Acids
- -Pathological Meta-Structures and Disease States
- --Amyloid in Alzheimers Disease and Amyloidoses
- --Vulnerable Plaque in Atherosclerosis
- --Imaging Sites of Inflammation and Apoptosis.
- -Voltage-Sensitive Dyes
- 2.2. Probes and Signal Amplification Strategies
- -Radioactive Tracers for PET, SPECT and Scintigraphy
- -Molecular Imaging Probes with Visual or Infrared Output
- --Targeted Beacon Probes
- --Target-Activated Probes
- -Bioluminescence: Luciferin/Luciferase
- -Green Fluorescent Protein (GFP) and its Derivatives
- Chapter 3. Molecular Imaging in Clinical Practice
- 3.1. Advantages as Biomarkers
- 3.2. General Regulatory Issues Affecting Imaging Agents
- 3.3. Cancer: An Almost Ideal Clinical Application of Molecular Imaging
- -Lung Cancer
- -Breast Cancer
- --Advanced Research Technologies SoftScan
- -Ovarian Cancer
- -SPECT Receptor Imaging Agents for Neuroendocrine Tumors
- --Mallinckrodt Medicals OctreoScan
- --Diatides NeoSpect / Neotect (Technetium-99m depreotide)
- --Draximages Iodine-123-Iobenguane (metaiodobenzylguanidine,
MIBG)
- -Colon Cancer
- --Immunomedics, Inc.s CEA-Scan (arcitumomab)
- -Prostate Cancer
- -Lymphoma
- --Immunomedics LymphoScan (bectumomab)
- --Fluorescence Imaging of Cancer at Accessible Mucosal Sites
- 3.4. Cardiovascular Disease
- -Minor but Growing Applications of MI in Cardiovascular Imaging
- --Draximage/Molecular Targeting Technologys AmiScan
- --Draximages Fibrimage
- --Agenixs ThromboView
- --Investigational Agents
- 3.5. Inflammation and Infection
- -Numerous Applications, Limited MI Options
- --Palatin Technologies NeutroSpec (Leutech;
[99mTc]-fanolesomab)
- --Draximages Infecton (Tc-99m labeled ciprofloxacin)
- -Investigational Agents
- --LeukoScan (Tc-99m sulesomab)
- --Tc-99m-RP-128
- --Tc-99m RP-517
- 3.6. Parkinsons and Alzheimers Diseases
- 3.7. Summary
- Chapter 4. Molecular Imaging in Research and Development
- 4.1. Molecular Imaging as an Integral Part of Clinical Development
- Brain Disorders
- --Alzheimers Disease
- --Parkinsons Disease
- --Amyotrophic Lateral Sclerosis
- --Ischemic Stroke
- -Monitoring Treatment Response with Cancer Drugs
- --Malignant Glioma
- --Monitoring Progression of Pre-Melanoma
- --A Combined Marker for Glutamatergic Neurotransmission and
Prostate Cancer
- -Peripheral Vascular Disease
- -Infection
- -Monitoring Gene Therapy and Advancing Vector Development
- --Imaging of Transgene-Induced Angiogenesis
- --Suitability of New Vector Constructs
- 4.2. Small Animal Imaging in Drug Development
- -Disease-Specific Applications of Small Animal Imaging
- --Prion Diseases
- --p53 Tumor Suppressor Protein
- --Models for Proto-Oncogenes and Their Ligands
- 4.3. Molecular Imaging in Drug Discovery and Lead Characterization
- -Procedure for Using Cell-Based Molecular Imaging
- -Primary and Secondary Applications of Cell-Based MI in Drug
Discovery
- --Lead Characterization
- --Lead Optimization
- -New Avenues Toward Target Validation
- -Basic Research in Cell Biology
- Chapter 5. Molecular Imaging as a Business
- 5.1. The Clinical Market for Molecular Imaging
- -PET as the Dominant Molecular Imaging Modality in Clinical
Practice
- -Combined PET/CT and SPECT/CT Modalities -- Boosters for Clinical
Molecular -Imaging
- 5.2. Small Animal Imaging: An Emerging Key Market for Preclinical Drug
Development
- 5.3. General Characteristics of the Molecular Imaging Market
- 5.4. Expert Commentaries
- -Merck
- -Pfizer
- -CTI Molecular
- -Genentech
- -Stanford
- -Johns Hopkins
- -GammaMedica
- -Novartis
- 5.5. Selected Company Profiles
- -Siemens Medical Solutions
- -GE Healthcare
- -Philips Medical Systems -- Molecular Imaging Unit
- -CTI Molecular Imaging
- -Applied Imaging Corp.
- -Norak Biosciences, Inc.
- -GammaMedica, Inc.
- -Kereos, Inc.
- -OptoSonics, Inc.
- -Xenogen Corp.
- -Molecular Imaging Research, Inc.
- -Visen Medical, Inc.
- 5.6. The Business Outlook for Molecular Imaging
- Appendix. Important Societies and Institutions
- Glossary
- Index
